ImmuPharma PLC (LON:IMM) has confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.
The specialist drug discovery and development company said 200 patients have been successfully recruited and dosed, with top line results remaining on track to be reported in the first quarter of 2018.
WATCH: Immupharma 'looking forward and planning for success' with Lupuzor
Commenting on the trial update, ImmuPharma’s chairman, Tim McCarthy, said: "We are delighted to announce this significant milestone that all patients have now completed dosing in this pivotal Phase III trial for Lupuzor™.”
READ: ImmuPharma banks extra £600,000 from Lanstead agreement
He added: “Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018."